Syncom Formulations (India) Ltd. is a key player in the pharmaceutical sector, known for its innovative products and cost-effective solutions. With a current share price of ₹20.12, the company holds promise for future growth. Here’s an in-depth analysis of its share price predictions from 2024 to 2040.
About Syncom Formulations
Syncom Formulations is an Indian pharmaceutical company specializing in manufacturing and marketing formulations across various therapeutic segments. It serves both domestic and international markets, focusing on affordability and quality.
Company Details
Founded: 1988
Headquarters: Indore, Madhya Pradesh, India
Sector: Pharmaceuticals
Products: Tablets, Capsules, Syrups, Ointments
Market Reach: India and Exports
Promoter Details
Promoter Name
Holding (%)
Institutional Investors
12.50
Retail & Others
87.50
Syncom Formulations Share Price Target 2024
Growth Factors:
Expanding export markets.
Focus on affordable healthcare products.
Minimum Target: ₹22
Maximum Target: ₹25
Syncom Formulations Share Price Target 2025
Key Drivers:
Increased investment in R&D for new formulations.
Growth in the domestic healthcare sector.
Minimum Target: ₹28
Maximum Target: ₹32
Syncom Formulations Share Price Target 2026 to 2030
Year
Minimum Target (₹)
Maximum Target (₹)
2026
35
40
2027
42
48
2028
50
58
2029
60
72
2030
75
90
Syncom Formulations Share Price Target 2035
Long-Term Catalysts:
Entry into niche therapeutic areas.
Diversification into over-the-counter (OTC) products.
Minimum Target: ₹110
Maximum Target: ₹135
Syncom Formulations Share Price Target 2040
By 2040, Syncom Formulations is expected to leverage its market presence and innovation to achieve robust growth.
Minimum Target: ₹150
Maximum Target: ₹180
Final Thoughts
Syncom Formulations has the potential to grow steadily in the coming years, driven by its focus on affordable medicines and international expansion. However, stock performance depends on market conditions and the company’s execution of its growth plans.
Disclaimer: Stock market investments are subject to risks. Perform thorough research or consult a financial advisor before investing. For more insights, visit moneyphobia.in!
Recent Posts
Income Tax Alert: ITR Filing Last Date for FY 2024-25 (AY 2025-26)
TikTok in India: The Buzz, the Ban, and What’s Really Happening
Wordle Answer Today (August 20, 2025): Hints and Full Solution Explained
Google Expands Store in India and Faces Global Play Store Challenges
Ola Electric Shares Recover Strongly After Heavy Fall in 2025
Gold Price Today: Rates Fall as Strong Dollar Impacts Market
Shreeji Shipping Global IPO Sees Strong Demand, GMP Suggests Listing Gains
India Approves ₹62,000 Crore Deal for LCA Tejas Mark 1A, HAL Shares Gain
Mangal Electrical and Gem Aromatics IPOs Draw Investor Attention with Steady GMP
Regaal Resources Makes Strong Market Debut with 39% Premium on Listing Day
Buchi Babu Tournament 2025 Begins with Exciting Performances
Mitchell Marsh Shines as Australia Battles South Africa in T20I and ODI Series